Colin Clark is Head of the EMEA Private Markets investment team. He is based in London.
Mr. Clark focuses on investments across Europe in the Consumer, Healthcare and TMT sectors. He currently serves on the Board of Directors of five portfolio companies in Europe: Pet Network International (Pet Supplies), Amethyst Radiotherapy (Specialised Radiotherapy Treatment Centres), Optimapharm (European CRO), Tallink (Ferry & Short Cruise Operator) and Prestige (Branded Biscuits & Wafers). He has held numerous board positions over the past 15 years in both public and private companies.
Prior to joining TRG in December 2013, Mr. Clark was a Partner at CVCI and a member of the investment team from 2003. During this period, he led and successfully exited multiple investments across Europe for CVCI. Before CVCI, Mr. Clark originated and structured project finance transactions for Citi across the EMEA region. From 1996 to 2000, he worked with Bank of Scotland in Edinburgh in various positions in project finance and acquisition finance.
Mr. Clark has a bachelor’s degree in Accountancy and Management from the University of Dundee, Scotland and is a qualified Chartered Accountant and a member of the Institute of Chartered Accountants of Scotland.